Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 2/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496130 | 1.00 | BACE1 (0.35) | BACE1CYP26B1NAMPTFLT3NR1H4 | |
| SCHEMBL228506 | 0.98 | BACE1 (0.35) | BACE1CYP26B1NAMPTFLT3NR1H4 | |
| SCHEMBL228505 | 0.98 | BACE1 (0.35) | BACE1CYP26B1NAMPTFLT3NR1H4 | |
| SCHEMBL223697 | 0.94 | BACE1 (0.36) | BACE1CYP26B1FLT3NR1H4PDGFRB | |
| SCHEMBL223698 | 0.94 | BACE1 (0.36) | BACE1CYP26B1FLT3NR1H4PDGFRB | |
| SCHEMBL225230 | 0.93 | BACE1 (0.36) | BACE1NAMPTFLT3NR1H4FOLH1 | |
| SCHEMBL225231 | 0.93 | BACE1 (0.36) | BACE1NAMPTFLT3NR1H4FOLH1 | |
| SCHEMBL3527888 | 0.92 | SENP1 (0.34) | BACE1NAMPTFLT3FOLH1SIRT2 | |
| SCHEMBL3527884 | 0.92 | SENP1 (0.34) | BACE1NAMPTFLT3FOLH1SIRT2 | |
| SCHEMBL227126 | 0.92 | BACE1 (0.37) | BACE1NAMPTFLT3NR1H4FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | BACE1 1615/4885CYP26B1 494/4885NAMPT 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.